Basic Daclatasvir Information

• INN (International Nonproprietary Name): Daclatasvir
• Brand names available in United Kingdom: Daklinza
• ATC Code: J05AP07
• Forms & dosages: Tablets 30 mg, 60 mg
• Manufacturers in United Kingdom: Bristol-Myers Squibb
• Registration status in United Kingdom: Prescription only
• OTC / Rx classification: Prescription only

Everyday Use & Best Practices

Health concerns often lead to confusion regarding the best practices for taking daclatasvir, particularly in relation to the timing and meal considerations. To ensure the effectiveness of this antiviral treatment, patients should focus on consistency.

Morning vs Evening Dosing

Establishing a regular dosing routine is crucial for enhancing the effectiveness of daclatasvir. It's advised that patients choose a time that fits seamlessly into their daily routine, be it morning or evening. An adaptive approach centred on personal lifestyle increases adherence to the treatment plan. For many, taking the medication in the morning alongside breakfast helps solidify this habit.

Taking with or without Meals (UK Diet Habits)

Daclatasvir can be taken with or without food, which provides flexibility. However, aligning the dosing with meals could improve adherence. A hearty breakfast, typical in UK culture, serves as an excellent reminder for many patients. Those who opt for morning doses may find that taking their medication with breakfast fits perfectly into their daily practices, ultimately supporting their treatment adherence.

Safety Priorities

Prioritising safety when taking daclatasvir is just as vital as understanding its use. Being informed can help prevent adverse reactions and ensure effective treatment.

Who Should Avoid It (MHRA Warnings)

The Medicines and Healthcare products Regulatory Agency (MHRA) has clear guidelines regarding who should avoid daclatasvir. Those with known hypersensitivity to daclatasvir or any of its components should not use this medication. Moreover, co-administration with strong CYP3A inducers — such as rifampicin and phenytoin — is strongly discouraged as these can drastically reduce daclatasvir's effectiveness.

Activities to Limit (Driving, Work Safety)

Potential side effects, including fatigue and dizziness, warrant caution around activities that require full concentration, such as driving or operating heavy machinery. It's essential for anyone in safety-sensitive roles to address their use of daclatasvir with their healthcare provider. This conversation can help ensure their ability to perform tasks safely isn't compromised.

Dosage & Adjustments

Understanding the appropriate dosage and needed adjustments can significantly impact the treatment journey for individuals on daclatasvir.

General Regimen (NHS Guidance)

The NHS recommends a standard dosage of 60 mg of daclatasvir taken orally once daily. It's typically prescribed in conjunction with other direct-acting antivirals like sofosbuvir. Adhering to NHS guidance is crucial for maximising the efficacy of the treatment for hepatitis C.

Special Cases (Elderly, Comorbidities)

No specific dosage modification is generally required for elderly patients unless they have renal impairment or other comorbid conditions. Nevertheless, healthcare providers should maintain close monitoring of these individuals. Adjustments might be necessary based on existing health conditions that could influence the body’s response to daclatasvir.

User Testimonials

Positive Reports from UK Patients

Hepatitis C can be a difficult condition to manage, but many patients in the UK have been positively impacted by daclatasvir. These individuals often share their journeys, noting significant improvements in their health outcomes. Reports commonly highlight successful treatment regimens that have led to sustained virologic responses. This means that the virus is no longer detectable in their blood, giving them hope and reclaiming their quality of life.

Patients frequently mention fewer hospital visits since starting treatment with daclatasvir, which contributes to a more manageable daily routine. The ease of use, as a daily oral medication, allows for better adherence to treatment plans. Many testimonials echo sentiments of gratitude, expressing appreciation for not only the drug's effectiveness but also for the support received from healthcare professionals guiding them through their recovery.

Common Challenges

Despite the positive feedback, challenges remain for some patients navigating their treatment with daclatasvir. Many have voiced their concerns on platforms such as Patient.info and NHS forums. The most common issues include:

• Dealing with side effects like fatigue, which can impact daily activities.
• Confusion regarding medication instructions and potential drug interactions.
• Accessing prescriptions, especially in remote areas or during times of high demand.

This feedback is invaluable, as it highlights the need for continuous support and education from healthcare providers, ensuring all patients feel empowered and informed throughout their treatment journey.

Buying Guide

Pharmacy Sources

When considering purchasing daclatasvir, also known by its brand name Daklinza, patients will find it readily available at major pharmacy chains across the UK. Prominent sources include:

• Boots
• LloydsPharmacy
• Superdrug

Patients should remember to check stock availability regularly, as demand can fluctuate. They may also discuss with their healthcare provider for more guidance on where to obtain their medications safely.

Price Comparison

The cost of daclatasvir varies depending on how it’s purchased. When obtained through NHS prescriptions in England, patients might incur a prescription charge. This fee can be a concern for those on a tight budget. In Scotland, Wales, and Northern Ireland, daclatasvir may be available to patients free of charge under the NHS.

For those considering private prescriptions, comparing prices across different pharmacies is recommended to find the best deals. Understanding these options can lead to significant savings and ensure patients can afford their essential medication.

What’s Inside & How It Works

Ingredients Overview

Daclatasvir contains the active ingredient daclatasvir, categorised as a direct-acting antiviral (DAA). It specifically functions as an NS5A inhibitor, targeting the hepatitis C virus replication complex. Knowing what’s in a medication plays an important role in helping patients understand its safety and efficacy.

Mechanism Basics Explained Simply

Understanding how daclatasvir works can demystify the treatment process for patients. It operates by preventing the hepatitis C virus from replicating. Essentially, daclatasvir blocks a crucial protein needed by the virus, allowing the body’s immune system to clear the infection more effectively. This targeted approach represents a significant advancement in the treatment of hepatitis C, providing patients with a fighting chance against this challenging disease.

Main Indications

Approved Uses

The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared daclatasvir for treating chronic hepatitis C virus infections across multiple genotypes, particularly types 1 and 3. This medication is typically not prescribed alone but rather in combination with other direct-acting antivirals to enhance its efficacy, offering a comprehensive approach to treatment.

Off-Label Uses in UK Clinics

While daclatasvir is primarily indicated for hepatitis C, some clinicians may find it useful for off-label applications, depending on individual patient needs and clinical judgement. Patients should consult healthcare professionals before considering any off-label use, ensuring they fully understand the benefits and risks involved.

Interaction Warnings

Food Interactions (Alcohol, Tea/Coffee)

Patients undergoing treatment with daclatasvir should be cautious about food interactions. Alcohol intake should generally be avoided, given its potential to exacerbate liver issues associated with hepatitis C treatment. Patients must also consider the impact of beverages such as tea and coffee on the absorption of the medication. While moderate consumption is typically acceptable, excessive intake may hinder the effectiveness of daclatasvir.

Drug Conflicts (MHRA Yellow Card Reports)

The Medicines and Healthcare products Regulatory Agency (MHRA) has highlighted warnings surrounding interactions with other medications. Particular attention should be given to drugs that induce or inhibit the CYP3A enzyme, as these can significantly alter the effectiveness of daclatasvir. It’s essential for patients to inform healthcare providers about all medications and supplements they are taking. This transparency helps to avoid potentially harmful interactions and ensures a smoother treatment process.

Latest Evidence & Insights

Recent studies conducted across the UK and Europe between 2022 and 2025 have unveiled important insights into the efficacy and safety of daclatasvir. Research showcases that daclatasvir boasts a sustained virologic response rate exceeding 90%. This impressive statistic positions it as a formidable option in the ever-evolving treatment landscape for hepatitis C. Such findings provide reassurances to individuals navigating their treatment choices, reinforcing daclatasvir’s role in achieving successful patient outcomes.

Alternative Choices

For those exploring options beyond daclatasvir, several alternatives exist within the same pharmacological class. Other NS5A inhibitors include:

• Ledipasvir
• Velpatasvir
• Elbasvir

Each alternative presents unique benefits and drawbacks, such as variations in side effects, pill burden, and suitability for different patient profiles. Patients should engage in discussions with their healthcare providers to make informed decisions about their treatment regimens, ensuring they select the option best suited to their specific circumstances.

Regulation Snapshot

In the United Kingdom, daclatasvir is regulated by the MHRA, with accessibility through NHS prescriptions. This regulatory endorsement underscores the commitment to effectively manage hepatitis C, ensuring patients can access essential antiviral treatments. The inclusion of daclatasvir in NHS formularies signifies its recognized value in treating hepatitis C, reflecting a comprehensive approach to patient care.

FAQ Section

Many patients have common queries regarding daclatasvir. Below are some frequently asked questions:

• What should I do if I miss a dose of daclatasvir? If a dose is missed, take it as soon as remembered on the same day. If over 12 hours have passed, skip the missed dose and resume the regular schedule.
• Are there any long-term side effects I should be aware of? While most side effects are mild, concerns over long-term effects should be discussed with a healthcare provider.
• How will I know if the treatment is working? Regular follow-up appointments and lab tests will indicate the effectiveness of the treatment by monitoring viral load.

These responses aim to empower patients with knowledge, encouraging proactive engagement in their treatment journey.

Guidelines for Proper Use

UK Pharmacist Counselling Style

Pharmacists play a crucial role in patient education regarding the use of daclatasvir. Key discussion points should encompass the importance of adhering to the prescribed regimen, as consistent intake is vital for treatment success. Counselling should also focus on managing side effects effectively, thus enhancing the patient’s comfort during their treatment journey.

NHS Patient Support Advice

NHS offers a wealth of support services to assist patients undergoing hepatitis C treatment. This includes helplines for inquiries about treatment and access to support groups, wherein individuals can share experiences and gain insights from peers. These resources are invaluable for navigating the complexities of treatment and fostering a supportive community for those affected by hepatitis C.

City	Region	Delivery Time
London	Greater London	5–7 days
Manchester	North West	5–7 days
Birmingham	West Midlands	5–7 days
Edinburgh	Scotland	5–7 days
Bristol	South West	5–7 days
Liverpool	North West	5–7 days
Glasgow	Scotland	5–7 days
Cardiff	Wales	5–7 days
Leeds	Yorkshire and the Humber	5–7 days
Sheffield	Yorkshire and the Humber	5–7 days
Newcastle	North East	5–7 days
Nottingham	East Midlands	5–9 days
Brighton	South East	5–9 days
Southampton	South East	5–9 days
Coventry	West Midlands	5–9 days